Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

    Richard V. Clark, David Hermann, Glenn R. Cunningham, Timothy H. Wilson, Betsy Morrill, S. F. Hobbs
    TLDR Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
    In a study conducted on 399 patients with benign prostatic hyperplasia (BPH), the dual 5alpha-reductase inhibitor dutasteride was found to significantly suppress serum dihydrotestosterone (DHT) levels more effectively than the selective type 2 isoenzyme inhibitor finasteride. Participants were randomized to receive various doses of dutasteride, finasteride, or placebo once daily for 24 weeks. The highest dose of dutasteride (5.0 mg) resulted in a 98.4% decrease in DHT, and the 0.5 mg dose resulted in a 94.7% decrease, both of which were significantly greater reductions than the 70.8% decrease observed with 5 mg finasteride. Testosterone levels increased slightly but remained within the normal range across all treatment groups. Dutasteride was also well tolerated, with an adverse event profile similar to that of the placebo.
    View this study on academic.oup.com →

    Cited in this study

    Related